Mandelbaum J, Belaïsch-Allart J, Junca A M, Antoine J M, Plachot M, Alvarez S, Alnot M O, Salat-Baroux J
Laboratoire de Recherche en FIV et Biologie de la Reproduction, Hôpital Necker, Paris, France.
Hum Reprod. 1998 Jun;13 Suppl 3:161-74;discussion175-7. doi: 10.1093/humrep/13.suppl_3.161.
Human embryo cryopreservation represents an indispensable extension of in-vitro fertilization (IVF) programmes as long as they are based upon the recovery of a large number of oocytes. The most widely used procedures include the cryopreservation of human zygotes or embryos in early cleavage, using 1,2-propanediol and sucrose as cryoprotectants. Our results over a 10 year period (1986-1995) on 5032 thawed cycles involving 14 222 stored embryos make it possible to appraise the results and the contribution of embryo freezing to assisted reproduction. Embryos survived the freeze-thaw process in 73% of cases leading to 4590 transfers of 2.2 embryos (91% of thawed cycles). The clinical pregnancy rate per transfer was 16%, the live birth rate 12%, and the rate of babies born alive per transferred embryo was 6%. Embryo freezing monitored 10 years later produced an average of 8% of additional births. By then, 86% of stored embryos had been thawed for transfer to patients. Destruction or donation were required for only 8% of all frozen embryos and there was no news from the parental couple in relation to almost 6% of embryos. The fate of the vast majority of embryos was decided during the first 5 years of storage. Blastocyst cryopreservation is making new strides, thanks to co-culture systems and embryo selection. Micromanipulation procedures seem to have little impact on the outcome of embryo freezing. Human oocyte freezing is again clinically applied. Indeed, much of the concern about injuries to the oocyte structures through the freeze-thaw process do not seem to be justified, and the problems with frozen-thawed oocyte fertilization has been overcome using intracytoplasmic sperm injection (ICSI). As long as oocyte in-vitro maturation is not well controlled, better results will probably be obtained with mature oocyte cryopreservation. Emerging methods include the freezing of immature oocytes, follicles and ovarian tissue.
只要体外受精(IVF)项目基于大量卵母细胞的回收,人类胚胎冷冻保存就是这些项目不可或缺的延伸。最广泛使用的程序包括使用1,2 - 丙二醇和蔗糖作为冷冻保护剂,对人类受精卵或早期分裂期胚胎进行冷冻保存。我们在1986年至1995年的10年期间,对5032个解冻周期(涉及14222个储存胚胎)的研究结果,使得评估胚胎冷冻对辅助生殖的结果和贡献成为可能。在73%的情况下,胚胎在冻融过程中存活,导致进行了4590次2.2个胚胎的移植(占解冻周期的91%)。每次移植的临床妊娠率为16%,活产率为12%,每个移植胚胎的活产婴儿率为6%。10年后监测胚胎冷冻产生了平均8%的额外出生。到那时,86%的储存胚胎已被解冻用于移植给患者。所有冷冻胚胎中只有8%需要销毁或捐赠,并且几乎6%的胚胎没有来自亲代夫妇的消息。绝大多数胚胎的命运在储存的前5年就已确定。由于共培养系统和胚胎选择,囊胚冷冻保存正在取得新的进展。显微操作程序似乎对胚胎冷冻的结果影响不大。人类卵母细胞冷冻再次应用于临床。事实上,许多关于冻融过程对卵母细胞结构造成损伤的担忧似乎没有依据,并且通过胞浆内单精子注射(ICSI)已经克服了冻融卵母细胞受精的问题。只要卵母细胞的体外成熟没有得到很好的控制,成熟卵母细胞冷冻保存可能会获得更好的结果。新兴方法包括未成熟卵母细胞、卵泡和卵巢组织的冷冻。